Poulami Chaudhuri
Chief Executive Officer & Co-Founder Helex
Seminars
Monday 16th March 2026
Panel Discussion: Novel Delivery Modalities & Gene Therapy Approaches in PKD
2:00 pm
- Exploring gene therapy, antisense oligonucleotides, and CRISPR-based approaches
- Overcoming delivery barriers to the kidney
- Designing preclinical studies with translational relevance
- Regulatory considerations for first-in-human studies
Wednesday 18th March 2026
Panel Discussion: How Can Novel Modalities be Used to Meet the Unmet Needs in CKD?
10:30 am
- Balancing innovation with clinical feasibility and scalable development in kidney disease
- Addressing AAV’s narrow tropism: how do we translate promise into real-world therapies?
- Exploring whether targeted delivery strategies must be disease-specific to maximize impact
- Ensuring RNAi and oligonucleotide therapies achieve durable, clinically meaningful kidney knockdown
Monday 16th March 2026
Kidney-Targeted LNP Delivery as a Next-Generation Therapeutic for ADPKD: Challenges, Design & Translational Path
1:00 pm
- Strategies for achieving kidney tropism: tuning size, charge, PEGylation, and reabsorption pathways
- Balancing efficacy, immunogenicity, and safety in nonviral LNP delivery for renal cells
- Integrating EPIC-Cure design with LNP payloads to minimize off-target effects in ADPKD
- Path to translation: scale-up, regulatory considerations, and metrics for success in ADPKD clinical trials
